Target intelligence / Profile preview

Cytochrome c oxidase subunit 2 (MT-CO2)

Target
MT-CO2
Molecular classification
Enzyme, Mitochondrial respiratory chain protein, Oxidoreductase
01

Overview

Cytochrome c oxidase subunit 2 (MT-CO2) is a mitochondrially encoded protein forming an essential structural and functional component of complex IV (cytochrome c oxidase) in the mitochondrial electron transport chain. MT-CO2 is anchored in the mitochondrial inner membrane and plays a central role in electron transfer from cytochrome c to the catalytic core, contributing to the reduction of molecular oxygen to water. This process is essential for generating the proton gradient that drives ATP synthesis through oxidative phosphorylation. Dysfunction or mutations in MT-CO2 can result in severe mitochondrial diseases with variable presentations, including mitochondrial encephalomyopathy, myopathy, lactic acidosis, and organ-specific or multisystem dysfunction. Rare mutations act by disrupting electron transport, reducing ATP production, and promoting excessive reactive oxygen species formation, with disease severity depending on the mutation type and load.

Other names
MT-CO2COX2COIICOXIIMTCO2CO2Cytochrome c oxidase polypeptide IIhCOX2
02

Mechanism of action

Not targeted by specific drugs for therapy; mechanistically, inhibition leads to respiratory chain blockade, impaired ATP production, and increased reactive oxygen species

03

Biological functions

Electron transportOxidative phosphorylationCellular respirationATP synthesisReduction of oxygen to water
04

Disease associations

Mitochondrial disease (including mitochondrial myopathy, encephalopathy, lactic acidosis, stroke-like episodes, and nonsyndromic/syndromic mitochondrial diseases)Huntington’s disease (as a biomarker)Stomach cancer (as a biomarker)Encephalomyopathy
05

Safety considerations

Direct inhibition or dysfunction leads to severe impairment of cellular energy metabolism, lactic acidosis, multiorgan dysfunctionHigh risk if blocked or mutated: mitochondrial disorders, potential fatal energy crisis
06

Interacting drugs

None reported as direct clinically used drugs targeting MT-CO2. (Cytochrome c oxidase inhibitors affecting the complex include cyanide and azide, but they are not therapeutic agents.)
07

Biomarkers

Huntington’s disease (biomarker)Stomach cancer (biomarker)

Beyond the preview

Go deeper on Cytochrome c oxidase subunit 2 (MT-CO2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytochrome c oxidase subunit 2 (MT-CO2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call